Tag Archives | genomics personalized medicine

Regulatory News for Rare Disease Products-Hot Stocks: BLUE,ICPT,SRPT …Updates

Update-1 See Chart below of Emerging Orphan drug players in comparison to leaders ALXN and BMRN. Update 5/21 on BLUE gene therapy for Gene therapy for sickle cell disease Will add to gene therapy watch list the following Company:Spark Therapeutics, Inc. (ONCE) , market cap $1.66B, $9.55 Cash/Sh., up 35% YTD focused in genetic diseases […]

Continue Reading 0

Biotech Buzz Is Broken…Update 4/30…#2

Gilead (GILD) Gilead Beats Q1 Estimates: $7.4B Sales HCV , EPS $2.94, stock up 2% after hours XBI Down Another 4% Down 12.84% in Five Days Weak Tape and Sell-Off Continues…4/30…NASDAQ at 4991 XBI down 1.6% now at 2/24 lows at 212 High fliers hit with profit taking…ADRO, AGIO, JUNO, KITE etc. Large cap Celgene […]

Continue Reading 0

Biotechs Lag In Snap-Back Rally: CAR-T

Big Earnings Week-AACR Data Disappoints Roller Coaster Market This will be a big week for the market with 25% of all S&P companies reporting earnings. There is a broad rally today in all major indices up over 1% with the DOW leading helped by AAPL up 2.4% on more bullish prospects for the Apple Watch. […]

Continue Reading 0

Biotech Bull Market: Trends to Watch in 2015… #3

Biotech Sector Moves Up In Tiny Steps Risk Remains On AACR Next Week Will Move Cancer Stocks Biotech indices and ETFs are trying to hit new highs but momentum is easing and trading is choppy. Nonetheless we are moving up from the brief correction near channel lows at the end of Q1. Sentiment remains strong. […]

Continue Reading 0

Biotechs Roaring Back: Do They Sense A Deal? Update -1 ABBV/PCYC

Whoa! $261.25 And the winner is Abbvie (ABBV) for $21B! Pharmacyclics Buzz Is Back¬† Biotech stocks covered the green screen today, despite a listless general market, driven by deal talk regarding Pharmacyclics (PCYC). Q4 2014 sales of their potential blockbuster drug Imbruvica for chronic lymphocytic leukemia hit $185M and is forecasted to hit the $1B […]

Continue Reading 0